Pentetic acid 20.8mg kit for radiopharmaceutical preparation
Requires a prescription from a doctor or prescriber
Pentetic acid, also known as diethylenetriaminepentaacetic acid (DTPA), is a synthetic polyamino carboxylic acid with eight coordinate bond forming sites that can sequester metal ions and form highly stable DTPA-metal ion complexes.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Pentetic acid
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Pentetic acid
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the TechneScan brand family (generic: Pentetic acid)
MHRA licensed products
View all licensed products for Pentetic acid on the MHRA register
Technescan DTPA kit for radiopharmaceutical preparation
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Trials: 2 · 1965–2026
Showing the 50 most relevant studies, sorted by most relevant.
Wei Jia, G. Xie, Weiping Jia
Nature reviews. Gastroenterology & hepatology, 2017
J. Gootenberg, Omar O. Abudayyeh, Jeong Wook Lee, et al.
Science (New York, N.Y.), 2017
P. Chomczyński, Nicoletta Sacchi
Analytical biochemistry, 1987
H. Ohkawa, N. Ohishi, K. Yagi
Analytical biochemistry, 1979
V. L. Singleton, J. Rossi
American Journal of Enology and Viticulture, 1965
D.A. Bossio, K.M. Scow
Microbial Ecology, 1998
Eric Jauniaux, Adrian Watson, Graham Burton
American Journal of Obstetrics and Gynecology, 2001
Hong Xie, J.J. Pasternak, Bernard R. Glick
Current Microbiology, 1996
Jillian Belgrad, H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics, 2024
Randy M. Becker, Guoyao Wu, Joseph A. Galanko, et al.
The Journal of Pediatrics, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
18.5-31.8 min
Mechanism
The calcium and zinc trisodium salts of DTPA achieve the therapeutical potential…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
20%
Half-life
18.5-31.8 min
Protein binding
[A32508]
…
Volume of distribution
17 L
Metabolism
[A32511]
Elimination
[L2243]
It is predominantly excreted by the kidney and it is not excreted by non-renal routes to any significant extent.[T168]…
Clearance
80-120ml/min
[A32508]
…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[A32501]
It is FDA approved for the treatment of individuals with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.
[L2243]
Due to the pharmacokinetic elimination by the kidneys, pentetic acid conjugated with technetium Tc-99m is being used clinically to estimate physiological parameters such as glomerular filtration rat and effective renal plasma flow.[T168]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 732 interactions
[A32508]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A32501]
When inhaled, the absorption is of about 20% of the administered dose.
[A32511]
[A32508]
It is reported that DPTA is negligibly bound to alpha1-antitrypsin.[T168]
[A32511]
[L2243]
It is predominantly excreted by the kidney and it is not excreted by non-renal routes to any significant extent.[T168]
[A32508]
The reported clearance rate in patients with normal renal function is 80-120ml/min.[T168]
Proteins that carry this drug through the body
The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Pentetic acid
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72